AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05726513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Weaning trial - Low support, zero positive end-expiratory pressure
Description: The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
Study NCT05726513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Weaning trial - Zero support, zero positive end-expiratory pressure
Description: The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with 0 pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
Study NCT05012774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Recognition Training
Description: Training for each training arm takes place over 10 sessions carried out at home. on the participant's own computer without experimenter direct supervision. Pre- and post-training tests are carried out under experimenter supervision.
Study NCT05350813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of the PCT plasma levels
Description: antibiotic treatment duration will be based on PCT plasma levels
Study NCT05350813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice based on guidelines
Description: antibiotic therapy duration will be determined by the type of infection, microbiological results and clinical, biological and/or radiological evolution, according to the usual practice based on guidelines.
Study NCT05522946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gameplay between parent and child or adolescent with or without a disability
Description: Parent and child or adolescent will play the game using the provided sensors for 10-15 minutes total. Depending on the cognitive and/or physical ability of the child or adolescent, the two may take turns wearing the sensors or if the child or adolescent does not have the physical or cognitive ability to deliberately touch the sensor, then the child or adolescent will wear the sensors and the parent will touch the sensors in order to move the game forward.
Study NCT04489732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells
Description: Single dose, starting at~* Dose Level 0: 10 (8-12) x 10\^6 injected into one submandibular gland on Day 1~Sub-study for second injection after primary objectives met, 10 (8 - 12) x 10\^6 MSCs will be offered for injection into each participant's contralateral submandibular gland
Study NCT04747223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Run Gait Retraining
Description: Running step rate will be retrained by real-time biofeedback via a watch accelerometer. Recent literature showed that performing gait retraining by altering step rate reduces loading rates and joint stress that are associated with lower extremity injuries (Wilson et al 2014, Lenhart et al 2014, Heidersheit et al 2011).
Study NCT05160298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,2% Injectable Solution
Description: Echo-guided bilateral erector spinae block
Study NCT05160298 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Sham block
Study NCT06044506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Natural Killer Cell Therapy
Description: The therapy will be administered intravenously
Study NCT06044506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinimacs Plus
Description: The CliniMACS Plus device is an automated cell separation tool that uses MACS Technology. It incorporates a flexible system designed for isolating clinically labeled cells using MicroBeads.
Study NCT05629299 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Samples
Description: Men will give semen, saliva, skin, urine and blood specimens
Study NCT06456476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ERCP
Description: ERCP used only if needed in some patients
Study NCT06216652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: downhill walking
Description: All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the first group performed downhill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
Study NCT06216652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: uphill walking
Description: All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the second group performed uphill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
Study NCT06216652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking with no incline
Description: All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the third group performed walking with no incline walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
Study NCT05444634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction Card
Description: Suitable for children over 3 years old. 1 set of 32 pieces of thick cardboard cards It has been prepared by child development experts in line with pedagogical principles.~Size: 13cm x 8cm, Each card illustrates the skills and actions the children do.
Study NCT05444634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Brain Shaped Stress Ball, White rope in the form of mesh around the inner silicone Size: Approx 2.4 inches (6 cm), Color: Colorful, When squeezed, the silicone structure comes out in the mesh spaces and turns into a bunch of grapes.
Study NCT04681053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Powder
Description: - Administration through inhalation (6mg) BID for 3 days
Study NCT04718805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
Study NCT04718805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
Study NCT04718805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
Study NCT06512844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) Intervention
Description: The MBSR training program consist of 8-week group session with the duration of 45-60 minutes each. Participants of the experimental group were given Mindfulness based stress reduction intervention in which they practice different mindfulness techniques. Each week focused on motor, cognitive and emotional issues of students with physically disabled. All the techniques also included psycho education
Study NCT05692869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Administered orally.
Study NCT05692869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Administered orally.
Study NCT04718805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
Study NCT04718805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat FDC
Description: Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
Study NCT05692869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABPM and Wearable Novel Devices
Description: ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
Study NCT05692869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No intervention during this period (Control Period)
Study NCT05435989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reduced extended high-frequency audibility
Description: This study examines the effects of low-pass filtering speech on speech perception.
Study NCT05055401 — intervention group
Intervention type: PROCEDURE
Intervention: Direct Laryngoscopy
Description: The participant will perform a direct laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under limited cervical range of motion.
Study NCT05055401 — intervention group
Intervention type: PROCEDURE
Intervention: Laryngeal Mask Airways
Description: The participant will perform LMA placement on a Laerdal SimMan 3G under healthy conditions and under full tongue edema.
Study NCT05055401 — intervention group
Intervention type: PROCEDURE
Intervention: Video Laryngoscopy
Description: The participant will perform video laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under half tongue edema with pharyngeal obstruction.
Study NCT06328218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Gymnastics Training
Description: This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
Study NCT04558164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Theta Burst Stimulation
Description: Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80-100% of motor threshold (MT).
Study NCT04558164 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Theta Burst Stimulation
Description: Sham stimulation will be delivered at 0-10% of motor threshold (MT), with all other parameters matching the active TBS condition.
Study NCT05044923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Epidural Spinal Stimulation
Description: Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
Study NCT05802927 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DSF
Description: Diabetes-specific formula
Study NCT05802927 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast 1
Description: Noodle Soup
Study NCT05802927 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast 2
Description: Glutinous rice
Study NCT04785196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
Study NCT04785196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
Study NCT05683145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy for Insomnia
Description: This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
Study NCT05503199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of one Perclose ProGlide or ProStyle (Abbott Vascular) and one Angio-Seal (Terumo).
Description: Combined suture- and plug-based VCD strategy after TF-TAVI.
Study NCT05503199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of two ProGlides or ProStyles (Abbott Vascular).
Description: Pure suture-based VCD strategy after TF-TAVI.
Study NCT05408247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 2400mg/day
Study NCT05408247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT06212752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab coformulated with hyaluronidase
Description: MK3475A SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Study NCT06212752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim will be administered as per the schedule specified for the arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim will be administered as per the schedule specified for the arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated filgrastim
Description: Pegylated filgrastim will be administered as per the schedule specified for the arm.
Study NCT06212752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated filgrastim
Description: Pegylated filgrastim will be administered as per the schedule specified for the arm.
Study NCT05807906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality application
Description: The patient will continue to monitor the virtual reality application during the fistula puncture procedure.
Study NCT03863145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-10
Description: CB-03-10, 100 mg capsule for oral use
Study NCT04648137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
Description: single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
Study NCT06467539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB plus AO
Description: oral, for 24 weeks
Study NCT06467539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAOIB plus placebo
Description: oral, for 24 weeks
Study NCT06228495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Intervention for Active Recovery
Description: Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy.
Study NCT06228495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Intervention for Active Recovery
Description: Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy.
Study NCT04773821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted biopsies
Description: Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
Study NCT04235322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LHERP®
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study NCT04235322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study NCT04648137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Control intervention: Placebo
Description: Identical placebo (only mannitol) capsules
Study NCT05676970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth: Wellness and Vaccination
Description: Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.
Study NCT05676970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleHealth: Wellness Only
Description: Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
Study NCT05157555 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Description: quality of life assessment
Study NCT06100770 — intervention group
Intervention type: DEVICE
Intervention: Aveir AR Leadless Pacemaker
Description: This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.